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Running title: Genetic analysis of ACCs 
 
ABSTRACT 
Aims: Acinic cell carcinoma of the breast (ACC) is a rare histologic form of triple-negative 
breast cancer (TNBC). Despite its unique histology, targeted sequencing analysis has failed 
to identify recurrent genetic alterations other than those found in common forms of TNBC. 
Here, we subjected three breast ACCs to whole-exome and RNA-sequencing, seeking to 
define whether they would harbor a pathognomonic genetic alteration. 
Methods and Results: Tumor and normal DNA and RNA samples from three breast ACCs 
were subjected to whole-exome sequencing. Somatic mutations, copy number alterations, 
mutational signatures and fusion genes were determined using state-of-the-art 
bioinformatics methods. Our analyses revealed TP53 hotspot mutations associated with loss 
of heterozygosity of the wild-type allele in two cases. Mutations affecting homologous 
recombination (HR) DNA repair-related genes were found in two cases, and an MLH1 
pathogenic germline variant was detected in one case. In addition, copy number analysis 
revealed the presence of a somatic BRCA1 homozygous deletion and focal amplification of 
12q14.3-12q21.1, encompassing MDM2, HMGA2, FRS2 and PTPRB. No oncogenic in-
frame fusion transcript was identified in the three breast ACCs analyzed. 
Conclusions: No pathognomonic genetic alterations were detected in the ACCs analyzed. 
These tumors have somatic genetic alterations similar to those of common forms of TNBC 
and may display HR deficiency or microsatellite instability. These findings provide further 
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insights as to why ACCs which are usually clinically indolent may evolve into or in parallel 
with high-grade TNBC.  
 
KEYWORDS: breast cancer, massively parallel sequencing, acinic cell carcinoma, DNA 
damage repair 
 
INTRODUCTION 
Acinic cell carcinoma of the breast (ACC) is an exceedingly rare special histologic type of 
breast cancer.1 ACCs of the breast are morphologically similar to their salivary gland 
conterparts, and are characterized by infiltrative microglandular or solid-nest structures 
composed of cells with diffuse serous differentiation with abundant eosinophilic to 
amphophilic cytoplasm and coarse or fine granules resembling Paneth cells.2 Areas 
composed of clear cells with hypernephroid appearance or non-specific glandular cells 
may be present.2, 3 Despite their triple negative phenotype, pure ACCs of the breast are 
low-grade carcinomas that usually follow an indolent clinical behavior,2 but may, 
nonetheless, be associated with or progress to high-grade triple negative breast cancer 
(TNBC).3, 4 
 
Previous studies from our group3, 5 and others4, 6 revealed that breast ACCs, 
microglandular adenosis (MGA) and atypical MGA, which show marked phenotypic 
overlap, display genetic alterations characteristic of common forms of TNBC, including 
complex patterns of copy number alterations (CNAs) and highly recurrent TP53 
mutations. These observations suggest that these entities may represent a low-grade 
triple-negative breast neoplasia family with no or minimal metastatic potential even when 
not associated with high-grade TNBC.5, 7  
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Notwithstanding their unique phenotype and previous efforts to characterize them by copy 
number and targeted sequencing analyses, no pathognomonic genetic alterations have 
been identified underpinning ACCs of the breast. Therefore, we sought to investigate the 
repertoire of somatic genetic alterations of pure ACCs of the breast by using whole-exome 
sequencing (WES) and RNA-sequencing. WES allowed for the detection of genetic 
alterations in genes not surveyed in previous studies of breast ACCs employing targeted 
sequencing panels. Additionally, RNA-sequencing analysis was performed to define whether 
pure ACC of the breast would harbor a highly recurrent fusion gene. 
  
METHODS 
Subjects and samples 
Following Institutional Review Boards approval, formalin-fixed paraffin-embedded tissue 
blocks of breast pure ACCs were retrieved from the archives of the Department of 
Pathology of the Nottingham University City Hospital  (Nottingham, UK). Samples were 
anonymized and reviewed by three pathologists (F.P., E.G-R. and J.S.R.-F). Of the two 
pure ACCs previously subjected to targeted capture sequencing as reported in Guerini-
Rocco et al.3, only case ACC12 was included in the present study due to tissue and 
nucleic acids availability. Cases ACC1 and ACC18 have not been previously reported and 
are unique to this study. 
 
WES and RNA-Sequencing analysis 
DNA was extracted from microdissected representative tumor and normal breast tissue, 
as previously described,8 and subjected to WES at the Integrated Genomics Operations 
(IGO) of Memorial Sloan Kettering Cancer Center (MSKCC), as previously described.9-11 
Tumor RNA samples were subjected to RNA-sequencing at the MSKCC’s IGO, as 
previously described.10, 11 Detailed analysis methods are described in the Supplementary 
Methods.  
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RESULTS 
All breast ACCs studied here featured an infiltrative microglandular growth pattern and 
cytoplasmic eosinophilic Paneth cell-like granules (Figure 1A-1H). In addition, ACC18 
focally displayed areas composed of clear cells with hypernephroid appearance (Figure 1H). 
All ACCs were of histologic grade 1, not associated with high-grade TNBC or any other 
lesions, including microglandular adenosis and lacked estrogen receptor (ER) and HER2 
expression (Supplementary Table 1).  
 
To determine whether breast ACCs would be underpinned by a pathognomonic genetic 
alteration, these cases were subjected to RNA-sequencing and WES (Supplementary 
Tables 2 and 3). RNA-sequencing analysis identified potential fusion transcripts only in 
ACC1, all of which were out-of-frame and likely constitute passenger events 
(Supplementary Table 2). One of these fusion genes, an out-of-frame TC2N-FBLN5 intra-
chromosomal fusion gene, displayed a low oncogenic potential as defined by OncoFuse 
(Supplementary Table 3) and was also found to be present in two ER-positive invasive 
breast carcinomas of no special type (IDC-NST) from The Cancer Genome Atlas (TCGA) 
dataset.12  
ACCs displayed a median of 173 (range, 92-230) non-synonymous somatic mutations as 
defined by WES (Supplementary Table 4), several affecting cancer genes (Figure 2A). Our 
analysis revealed clonal TP53 hotspot mutations associated with loss of heterozygosity 
(LOH) of the wild-type allele in two ACCs. In contrast, the TP53 wild-type ACC (ACC12) 
harbored a pathogenic MLH1 germline mutation (c.790+2dupT) and a clonal hotspot 
mutation in CTNNB1 (c.1004A>T, Figure 2A, Supplementary Figure 1 and 
Supplementary Table 4). Other likely pathogenic mutations included a truncating 
mutation in KMT2D (MLL2), a histone methyltranferase whose inactivation results in 
genome instability13 and is frequently mutated in common forms of TNBC14, associated 
with LOH in case ACC1 (Figure 2A, Supplementary Figure 1 and Supplementary Table 
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4). No cancer gene other than TP53 was found to be mutated in >1 of the ACCs studied 
here.  
 
Copy number analysis revealed that ACC1 and ACC18 displayed complex copy number 
profiles, with multiple gains and losses and focal high-level amplifications, in contrast, 
ACC12 showed a rather quiet copy number profile (Figure 2B). Copy number alterations 
(CNAs) present in both ACC1 and ACC18 included gains of 1q, 2q and 8q and losses of 
3p, 12p, 12q, 14q, 17p and 17q. In line with previous studies reporting ACCs arising in 
BRCA1 germline mutation carriers, we identified a somatic homozygous deletion in 
17q21.31 encompassing BRCA1 in ACC18 (Figure 1B). In addition, we observed that 
ACC18 harbored a focal amplification in 20p12.3 encompassing PCNA, which encodes 
for Proliferating Cell Nuclear Antigen, a key promoter of processive DNA synthesis.15 
ACC1 was found to harbor a high-level amplification of 12q14.3-12q21.1, which 
encompasses several cancer genes, such as MDM2, HMGA2, WIF1, FRS2 and PTPRB. 
In contrast, and consistent with its DNA mismatch repair deficiency, ACC12 displayed a 
simple genome without detectable copy number alterations. 
 
We next sought to determine whether breast ACCs would display genomic features 
suggestive of HRD or other biological processes that would confer genomic instability. 
ACC1 was found to display a dominant signature 5, ascribed to aging (Figure 2C). 
ACC18, which harbored a BRCA1 homozygous deletion, displayed genomic features of 
HRD, including a dominant signature 3, related to homologous recombination DNA repair 
deficiency (HRD),16 along with other genomic features suggestive of HRD, such as a high 
large-scale state transitions (LST) score (24)17, a high telomeric allelic imbalance (NtAI) 
score (23)18 and a high number of ‘small deletions’ >5bps (Figure 2C and 
Supplementary Table 5). Although we did not identify somatic mutations in MLH1 or in 
other core MMR genes, ACC12, which harbored a pathogenic germline splice site mutation 
in MLH1 (c.790+2dupT), a key tumor suppressor of the mismatch repair (MMR) system 
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(Supplementary Table 4), displayed a dominant mutational signature 6, ascribed to 
defective MMR19 (Figure 2C), as well as high levels of microsatellite instability (MSI-H) as 
determined by MSIsensor20 (Supplementary Table 5). Consistent with these findings, 
this case additionally showed loss of MLH1 protein expression in the tumor by 
immunohistochemistry (Figure 2D). 
 
DISCUSSION 
Previous studies from our group and others have suggested that ACCs of the breast and 
MGA, entities with overlapping histologic characteristics, are part of the spectrum of low-
grade triple negative disease, and harbor genomic features indistinguishable from those 
of common forms of TNBC3, 5, 7, 21. Further supporting this notion, our study revealed few 
recurrently mutated genes, such as TP53, and complex copy number profiles. 
 
Most importantly, our findings provide further support to the association between breast 
ACC and HRD through BRCA1 inactivation. Our results demonstrate that ACC18 harbors 
a BRCA1 homozygous deletion (Figure 2C). In conjunction with previous reports by our 
group and others3, 22, loss-of-function alterations affecting BRCA1 concurrent with TP53 
somatic mutations seem not to be uncommon in breast ACCs, even in those lacking a 
high-grade TNBC component. Our findings, however, suggest the tantalizing possibility 
that both BRCA1 and TP53 loss of function may not be sufficient for a TNBC to display 
high-grade features and that inactivation of these two genes may not sufficient for the 
development of high-grade TNBC.3, 5  
 
Here we also described an ACC (ACC12) that lacked mutations affecting TP53, displayed 
a simple copy number profile, high MSI levels and a dominant signature 6 (MSI-related). 
This case arose in a patient carrier of a germline MLH1 splice-site mutation. Although we 
did not identify a somatic genetic alteration in MLH1, we cannot rule out that the second 
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MLH1 allele could have been inactivated by epigenetic silencing via promoter 
hypermethylation, as described in colorectal and endometrial carcinoma. 23, 24 
 
Our study has important limitations, including the small sample size, due to the rarity of 
this entity and the fact that only historical archival samples were available for analysis. 
We were unable to perform any methylation analyses to interrogate epigenetic silencing 
as a mechanism of inactivation of the second MLH1 allele in ACC12 owing to the lack of 
residual DNA from this case. Despite these limitations, our data lend further support to the 
notion that ACCs of the breast are genetically heterogeneous and display genomic 
features overlapping with those of common forms of TNBCs. These tumors appear not to 
be driven by a highly recurrent mutation or oncogenic fusion gene. Most importantly, our 
findings suggest that at least some ACCs of the breast may arise in the setting of HRD or 
MSI through distinct molecular mechanisms. Even though we could not establish a 
definitive causal link between BRCA1 mutations or MLH1 germline mutations and breast 
ACCs, our study demonstrates that HDR deficiency and MSI-H happen in ACCs, and that 
the ACCs analyzed displayed high levels of genetic instability (either HDR defects or MSI-
H). Additional studies on the genetic or epigenetic basis of breast ACCs are warranted. 
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FIGURE LEGENDS 
Figure 1. Histologic characteristics of acinic cell carcinomas of the breast.  
(A-B) Representative photomicrographs of hematoxylin and eosin (H&E)-stained acinic cell 
carcinomas of the breast (ACCs) from this study. (A-C) ACC1 displays an infiltrative growth 
(A) with microglandular features (B) and is composed of Paneth-like cells with coarse 
intracytoplasmic granules (C). (D-E) ACC12 displays a microglandular growth pattern (D) 
with cells featuring an amphophilic cytoplasm with fine granules (E). (F-H) ACC18 displays 
microglandular areas (F) composed of eosinophilic cells with coarse granules (G) and 
hypernephroid areas composed of clear cells (H). Scale bar, 200 μm (A, D), 50 μm (B, and 
E), 20 μm (C, G and H) and 100 μm (F). 
 
Figure 2. Repertoire of somatic mutations and mutational signatures of the acinic cell 
carcinomas of the breast.  
(A) Non-synonymous somatic mutations affecting cancer-related genes13–15 and mutations 
shared among cases identified in the acinic cell carcinomas of the breast (ACCs; n=3) 
subjected to whole-exome sequencing (WES). Cases are shown in columns and genes in 
rows. (B) Copy number plots depicting segmented Log2 ratios (y-axis) plotted according to 
genomic position (x-axis). Chromosomes are demarcated by alternating blue and gray colors 
(C) Mutational signatures of all somatic SNVs in breast ACCs (n=3). Pie charts indicate the 
proportion of the different mutational signatures identified in each case. (D) Representative 
hematoxylin and eosin micrograph of ACC12 arising in a patient with an MLH1 germline 
mutation (top) and micrograph depicting loss of MLH1 expression in the tumor cells (*). 
Normal breast (right lower corner) shows retention of MLH1 expression. Dashed line Scale 
bar, 50 μm. SNV, single nucleotide variant. Sig, signature; SNV, single nucleotide variant.  
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